Replies to post #560 on Bristol Myers Squibb (BMY)

[Johnny_C]

I could believe that clever shorts might have engineered a selloff and were waiting for the results

Would be funny if a buyout offer happens. I do think BMY is a big fish to swallow though. GILD has the cash. PFE has Eliquis in joint venture and has weighted their drug portfolio up to 50 to 60 percent oncology.

I bought after the takeout articles appeared, but I imagine any company would need some time to figure synergies, tax ramifications, debt payments and divesting out.

My prediction is if someone makes a run at them it will be after my first batch of options expire.

Some of the articles speculating a buyout give very compelling arguments but without healthcare bill, tax reform and drug pricing still anyone's guess, GILD needs to buy something but I have been thinking that for a year. If PFE could repatriot foreign money it would be a no brainer.

BMY has nice steady dividend though, and seems like a they have a nice long term portfolio.

If you do low cost bio's at all check out VTGN. I am thinking $40.00 if Phase II B a success. Sounds crazy but Naurex drug was bought by AGN for 600m cash and 1 bil on back end milestones. Naurex was intravenous and VTGN drug oral.

[2014shelby]

Agreed. BMY has created that doubt due their performance and subsequent drop in PPS and equity over the past year+

"I believe that there is a market sentiment to go bearish on BMY whenever there is doubt."